A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...

Sanofi and Regeneron's drug is already approved to treat atopic dermatitis and severe asthma in adults, and the green light in CRSwNP comes ... as its $36,000 list price is a huge premium on ...

Tezepelumab was linked to significantly reduced nasal polyp size and nasal congestion vs placebo in adults with severe CRSwNP.

Explore medication options for kidney disease and potential side effects. Learn the best treatment options to slow ...

This disconnect can lead to adults with cerebral palsy being prescribed medications that aren't the correct treatment for the source of their concerns, creating patterns of people taking drugs that ...

SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on ...

Implementing the Medicare $2 drug list model would have reduced out-of-pocket spending by 63% for Part D beneficiaries in 2021. The model caps cost-sharing at $2 for a 30-day supply of 101 generic ...

GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...

Calquence (acalabrutinib) has been effective, but side effects and new research suggest potential benefits of reducing or stopping the medication. Minimal residual disease (MRD) testing is a promising ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...

Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

Generic drug manufacturers have had to contend with increasing competition and tight profit margins in recent years. Slapping extra costs through tariffs could undermine their ability to do ...